AN2 Therapeutics ANTX 深 滬
等待開盤 08-05 09:30:00 美东时间
1.03
-0.030
-2.83%
華盛通- 最 高1.07
- 今 開1.06
- 成交量 5.33万股
- 最 低 1.03
- 昨 收 1.06
- 總市值 3108.10万
- 52周最高 1.675
- 市盈率 靜 --
- 換手率 0.00%
- 52周最低 0.95
- 委 比 45.80%
- 總股本 3017.57万
- 歷史最高 23.58
- 量 比 1.30
- 振 幅 3.77%
- 歷史最低 0.87
- 每 手 1
- 風險率 0.27%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Anterix Sets First Quarter Fiscal 2026 Earnings Conference Call for Wednesday, August 13, at 9:00 a.m. ET
<p>Anterix (NASDAQ: ATEX) announced it will host a conference call on August 13, 2025, at 9:00 a.m. ET to discuss its first quarter fiscal 2026 results. A press release will be issued on August 12, 2025. Interested participants must pre-register to join the live Q&A session. The call will be webcast live and available on Anterix’s Investor Relations website. A replay will be posted afterward. Anterix specializes in 900 MHz broadband solutions for...
07-22 15:30
AN2 Therapeutics Completed Its 200-patient Observational Study In Acute Melioidosis. The Study Evaluated Patients Receiving The Current Standard Of Care: IV Meropenem Or Ceftazidime
Study highlights high mortality despite standard of care and provides critical data to optimize design for upcoming proof-of-concept trial for epetraboroleObservational Study funded by the National Institutes of Health
06-30 19:11
AN2 Therapeutics Unveils Updated Investor Presentation
AN2 Therapeutics, Inc. ( ($ANTX) ) just unveiled an announcement. On June 11, 2...
06-11 19:59
AN2 Therapeutics Elects New Directors at Annual Meeting
AN2 Therapeutics, Inc. ( ($ANTX) ) has shared an announcement. On May 22, 2025,...
05-28 05:09
AN2 Therapeutics Q1 GAAP EPS $(0.35) Misses $(0.26) Estimate
AN2 Therapeutics (NASDAQ:ANTX) reported quarterly losses of $(0.35) per share which missed the analyst consensus estimate of $(0.26) by 34.62 percent. This is a 37.5 percent increase over losses of $(0.56) per share from
05-14 06:01
快讯 | AN2 Therapeutics Inc：预计现金流将资助运营至2028年
AN2 Therapeutics Inc: Cash Runway Anticipated to Fund Operations Into 2028
05-14 04:02
快讯 | AN2 Therapeutics报告2025财年第一季度财务业绩以及近期的业务和科学亮点
AN2 Therapeutics Reports First Quarter 2025 Financial Results and Recent Busine...
05-14 04:01
AN2 Therapeutics Faces Setback in Phase 3 Study
AN2 Therapeutics, Inc. ( ($ANTX) ) has issued an update. AN2 Therapeutics annou...
05-02 04:48
AN2 Therapeutics Reports 2024 Financials and Pipeline Progress
AN2 Therapeutics, Inc. ( ($ANTX) ) has released its Q4 earnings. Here is a brea...
04-04 11:53
美股大行评级 | 潜在涨幅53%！HIMS获机构上调目标价至61美元，维持“买入”评级
<span> <meta content="no-referrer" name="referrer"></span><p>https://static-hk.hstong.com/public/forum-v2/status/icon/50267976/originalpic/1101427780957868033.png</p><span style="color:#999999;">编者按：每日追踪华尔街最新评级与目标价，挖掘潜力股投资机会。</span><blockquote> <p><span style="color:#fa1432;"><strong>今日重点评级关注</strong></span></p></blockquote><p>• HC Wainwright & Co.：维持MiNK Therapeutics(INKT)"买入"评级，目标价从9美元升至35美元</p> <p>• D. Boral Capital：维持FiscalNote Ho
02-26 09:46
